Neurogenic atherosclerosis mediated by neuropeptide Y: Hardening of the evidence

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 7, 2003, Pages 1137-1139

  Sobey, Christopher G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL DAMAGE; EDITORIAL; ENDOTHELIUM CELL; HUMAN; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SYMPATHETIC NERVE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; NEUROPEPTIDE Y; RATS; RECEPTORS, NEUROPEPTIDE Y; TUNICA INTIMA;

EID: 0038448188     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000078582.90403.E6     Document Type: Editorial

References (16)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: stent restenosis study investigators. N Engl J Med. 1994;331:496-501.
3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99:2192-2217.
4. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Phannacol. 2000;35:S1-S7.
5. Julius S. The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens. 1996;18: 305-321.
6. Erlinge D, Yoo H, Edvinsson L, Reis DJ, Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs other growth factors and sympathetic cotransmitters. Am J Physiol. 1993;265:H1089-H1097.
7. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol. 2003;81: 177-185.
8. Zukowska-Grojec Z. Neuropeptide Y: a novel sympathetic stress hormone and more. Ann N Y Acad Sci. 1995;771:219-233.
9. Morris MJ, Cox HS, Lambert GW, Kaye DM, Jennings GL, Meredith IT, Esler MD. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997;29:137-143.
10. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83:187-195.
11. Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol. 1994;51:53-61.
12. Ericsson A, Hemsen A, Lundberg JM, Persson H. Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells. Exp Cell Res. 1991;192:604-611.
13. Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, Wing LM, Chalmers JP. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986;17:143-149.
14. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis. 2001;159:145-151.
15. Li L, Lee EW, Ji H, Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol. 2003;23:1204-1210.
16. Thorsell A, Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides. 2002;36:182-193.